IMNN Stock Overview
Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
My Notes
NewNotes are coming soon
Imunon, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.60 |
52 Week High | US$7.68 |
52 Week Low | US$1.26 |
Beta | 2.05 |
1 Month Change | -0.62% |
3 Month Change | 3.23% |
1 Year Change | -74.81% |
3 Year Change | -92.33% |
5 Year Change | -94.97% |
Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Celsion changes name to Imunon (IMNN)
Sep 19Celsion says additional data shows placcine vaccine works against COVID-19 in animal model
Sep 01Celsion Q2 2022 Earnings Preview
Aug 12Celsion adds Moderna chief commercial officer as CEO
Jul 19Is Celsion (NASDAQ:CLSN) Using Debt Sensibly?
Dec 07Is Celsion (NASDAQ:CLSN) Using Too Much Debt?
Aug 18What We Learned About Celsion's (NASDAQ:CLSN) CEO Compensation
Dec 01Celsion slips 4% on Q3 earnings miss
Nov 16Shareholder Returns
IMNN | US Biotechs | US Market | |
---|---|---|---|
7D | 2.6% | -0.8% | 1.7% |
1Y | -74.8% | 4.4% | -9.6% |
Return vs Industry: IMNN underperformed the US Biotechs industry which returned 4.5% over the past year.
Return vs Market: IMNN underperformed the US Market which returned -8.5% over the past year.
Price Volatility
IMNN volatility | |
---|---|
IMNN Average Weekly Movement | 7.8% |
Biotechs Industry Average Movement | 12.1% |
Market Average Movement | 6.7% |
10% most volatile stocks in US Market | 17.5% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: IMNN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: IMNN's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1982 | 29 | Corinne Le Goff | https://www.imunon.com |
Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies.
Imunon, Inc. Fundamentals Summary
IMNN fundamental statistics | |
---|---|
Market Cap | US$11.89m |
Earnings (TTM) | -US$26.89m |
Revenue (TTM) | US$500.00k |
23.8x
P/S Ratio-0.4x
P/E RatioIs IMNN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
IMNN income statement (TTM) | |
---|---|
Revenue | US$500.00k |
Cost of Revenue | US$11.72m |
Gross Profit | -US$11.22m |
Other Expenses | US$15.67m |
Earnings | -US$26.89m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -3.62 |
Gross Margin | -2,243.33% |
Net Profit Margin | -5,377.37% |
Debt/Equity Ratio | 14.5% |
How did IMNN perform over the long term?
See historical performance and comparison